Cover Image
市場調查報告書

卵巢癌治療藥的亞太地區市場 2020年:儘管有新上市,專利到期的化療方案仍保持獨佔狀態

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

出版商 GBI Research 商品編碼 329737
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
卵巢癌治療藥的亞太地區市場 2020年:儘管有新上市,專利到期的化療方案仍保持獨佔狀態 Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
出版日期: 2015年01月31日 內容資訊: 英文 126 Pages
簡介

亞太地區的卵巢癌治療藥市場,並非由於核准新藥物而主要由於通貨膨脹而擴大。該市場收益預計至2020年以年複合成長率5.1%達到4億1,760萬美元。

本報告提供卵巢癌相關概要與已上市產品、臨床實驗中產品趨勢,到2020年的市場發展預測、共同開發及授權等今後的策略相關考察,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 疾病的病理學
  • 症狀與診斷
  • 風險係數
    • 年齡
    • 繼承的遺傳基因變異
    • 一生排卵數的增加
    • 體重
    • 以前的症狀
  • 治療流程
    • 外科手術
    • 第一次化療
    • 維持療法
  • 復發疾病

第3章 已上市產品

  • Carboplatin
  • Paclitaxel
  • Gemcitabine
  • Topotecan
  • Pegylated Liposomal Doxorubicin
  • Yondelis
  • Avastin

第4章 產品平台

  • 各Phase別,給藥途徑開發平台概要
  • 各分子類型、作用機制、分子標的開發平台概要
  • 臨床實驗
    • 期間
    • 規模
    • 失敗率
    • 考察
  • 開發平台的後期階段的藥物
  • 考察

第5章 市場預測

  • 亞太地區
  • 印度
  • 中國
  • 日本
  • 澳洲
  • 促進要素與阻礙

第6章 交易契約

  • 授權
  • 共同開發

第7章 附錄

圖表

目錄
Product Code: GBIHC351MR

Executive Summary

GBI Research, a leading business intelligence provider, has released its latest research report, "Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches". The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).

Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.

Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.

Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes -

  • A brief introduction to OC, including the disease's pathogenesis, risk factors and diagnosis
  • In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
  • A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
  • Discussion of the drivers and barriers for market growth
  • In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals

Reasons to buy

  • The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
  • Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
  • Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Pathophysiology
    • 2.1.1. Ovarian Cancer - A Group of Distinct Diseases
    • 2.1.2. Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
  • 2.2. Symptoms and Diagnosis
  • 2.3. Risk Factors
    • 2.3.1. Age
    • 2.3.2. Inherited Genetic Mutations
    • 2.3.3. Greater Number of Lifetime Ovulations
    • 2.3.4. Weight
    • 2.3.5. Previous Medical Conditions
  • 2.4. Treatment Algorithm
    • 2.4.1. Surgery
    • 2.4.2. First-Line Chemotherapy
    • 2.4.3. Maintenance Therapy
  • 2.5. Recurrent Disease

3. Marketed Products

  • 3.1. Carboplatin
  • 3.2. Paclitaxel
  • 3.3. Gemcitabine
  • 3.4. Topotecan
  • 3.5. Pegylated Liposomal Doxorubicin
  • 3.6. Yondelis
  • 3.7. Avastin

4. Product Pipeline

  • 4.1. Overview of Pipeline by Phase and Route of Administration
  • 4.2. Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target
    • 4.2.1. Molecular Targets in the Developmental Pipeline
  • 4.3. Clinical Trials
    • 4.3.1. Clinical Trial Duration
    • 4.3.2. Clinical Trial Size
    • 4.3.3. Failure Rate
    • 4.3.4. Discussion
  • 4.4. Late-Stage Drugs in Developmental Pipeline
    • 4.4.1. Niraparib
    • 4.4.2. Olaparib
    • 4.4.3. Vargatef
    • 4.4.4. Trebananib
    • 4.4.5. Farletuzumab
    • 4.4.6. Karenitecin
  • 4.5. Discussion

5. Market Forecasts

  • 5.1. Asia-Pacific
    • 5.1.1. Overview
    • 5.1.2. Treatment Use Patterns and Revenues in Asia-Pacific Markets
  • 5.2. India
    • 5.2.1. Treatment Use Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Forecast
  • 5.3. China
    • 5.3.1. Treatment Use Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Forecast
  • 5.4. Japan
    • 5.4.1. Treatment Use Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Forecast
  • 5.5. Australia
    • 5.5.1. Treatment Use Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Forecast
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Deals

  • 6.1. Licensing Deals
    • 6.1.1. Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338
    • 6.1.2. PharmaMar Enters into Licensing Agreement with Janssen for Yondelis
    • 6.1.3. Hana Enters into Licensing Agreement with Tekmira
    • 6.1.4. AstraZeneca Enters into Licensing Agreement with Merck for MK-1775
    • 6.1.5. Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug
    • 6.1.6. Oasmia Enters into Licensing Agreement with Medison for Paclical
    • 6.1.7. Orion Enters into Agreement with Oasmia
    • 6.1.8. Ohio University Enters into Licensing Agreement with Phosplatin
    • 6.1.9. Genta Enters into Licensing Agreement with Daiichi Sankyo
    • 6.1.10. Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research
    • 6.1.11. NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300
  • 6.2. Co-development Deals
    • 6.2.1. Bristol-Myers Squibb Enters into Co-development Agreement with Ono Pharma
    • 6.2.2. Merck Enters into Co-development Agreement with Endocyte for Cancer Drug
    • 6.2.3. Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre
    • 6.2.4. Almac Discovery Enters into an Agreement with Queen's University Belfast for Drug Discovery

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-Filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-Registration
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Asia-Pacific
    • 7.2.2. India
    • 7.2.3. China
    • 7.2.4. Japan
    • 7.2.5. Australia
  • 7.3. Abbreviations
  • 7.4. Bibliography
  • 7.5. Research Methodology
    • 7.5.1. Coverage
    • 7.5.2. Secondary Research
    • 7.5.3. Primary Research
    • 7.5.4. Therapeutic Landscape
    • 7.5.5. Geographical Landscape
    • 7.5.6. Pipeline Analysis
  • 7.6. Expert Panel Validation
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: Ovarian Cancer Therapeutics, Histological Subtypes and Associated Genetic Mutations
  • Table 2: Ovarian Cancer Therapeutics, Affected Signaling Pathways in Ovarian Cancer, Associated Mutations and Effects on Cancer Development
  • Table 3: Ovarian Cancer Therapeutics, Ovarian Cancer Disease Staging
  • Table 4: Ovarian Cancer Therapeutics, Eastern Cooperative Oncology Group Performance Status Scores and Description
  • Table 5: Ovarian Cancer Therapeutics, Common Endpoints in Ovarian Cancer and Details of Criteria
  • Table 6: Ovarian Cancer Therapeutics, Rates of Sensory and Motor Neuropathy with Pegylated Liposomal Doxorubicin and Paclitaxel in Combination with Carboplatin (%), 2010
  • Table 7: Ovarian Cancer Therapeutics, Yondelis Phase III Clinical Trial, Patient Stratification by Platinum-Free Interval, 2010
  • Table 8: Ovarian Cancer Therapeutics, Poly ADP Ribose Polymerase Inhibitors Under Development, 2014
  • Table 9: Ovarian Cancer Therapeutics, Epidermal Growth Factor Receptor Inhibitors Under Development, 2014
  • Table 10: Ovarian Cancer Therapeutics, Mucin Inhibitors Under Development, 2014
  • Table 11: Ovarian Cancer Therapeutics, Aurora Kinase Inhibitors Under Development, 2014
  • Table 12: Ovarian Cancer Therapeutics, Average Clinical Trial Duration across Each Phase for Ovarian Cancer, across Oncology and Entire Industry (months), 2014
  • Table 13: Ovarian Cancer Therapeutics, Global, Patient Demographics of a Phase III Clinical Trial of Trebananib (%), 2011
  • Table 14: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Discovery Phase, 2014
  • Table 15: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Preclinical Phase, 2014T
  • Table 16: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, IND/CTA-Filed, 2014
  • Table 17: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2014
  • Table 18: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase II, 2014
  • Table 19: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase III, 2014
  • Table 20: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Pre-Registration, 2014
  • Table 21: Ovarian Cancer Therapeutics, Asia-Pacific, Market Forecast, 2013-2020
  • Table 22: Ovarian Cancer Therapeutics, India, Market Forecast, 2013-2020
  • Table 23: Ovarian Cancer Therapeutics, China, Market Forecast, 2013-2020
  • Table 24: Ovarian Cancer Therapeutics, Japan, Market Forecast, 2013-2020
  • Table 25: Ovarian Cancer Therapeutics, Australia, Market Forecast, 2013-2020
  • Table 26: Abbreviations

List of Figures

  • Figure 1: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, First-Line and Maintenance Therapies
  • Figure 2: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, First-Line and Maintenance Therapies
  • Figure 3: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Recurrent Disease: All Patients
  • Figure 4: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Recurrent Disease: All Patients
  • Figure 5: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Sensitive
  • Figure 6: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Sensitive
  • Figure 7: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Resistant
  • Figure 8: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Resistant
  • Figure 9: Ovarian Cancer Therapeutics, Global, Pipeline Distribution by Stage, Program Type and Route of Administration, 2014
  • Figure 10: Ovarian Cancer Therapeutics: Global, Pipeline by Molecule Type and Mechanism of Action, 2014
  • Figure 11: Ovarian Cancer Therapeutics, Global, Molecular Targets of the Developmental Pipeline, 2014
  • Figure 12: Ovarian Cancer Therapeutics, Global, Clinical Trial Duration (months), 2006-2014
  • Figure 13: Ovarian Cancer Therapeutics, Global, Clinical Trial Size (participants), 2006-2014
  • Figure 14: Ovarian Cancer Therapeutics, Global, Clinical Trial Failure Rate and Reasons for Failure (%), 2006-2014
  • Figure 15: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: All Patients
  • Figure 16: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: All Patients
  • Figure 17: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Sensitive
  • Figure 18: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Sensitive
  • Figure 19: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Resistant
  • Figure 20: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Resistant
  • Figure 21: Ovarian Cancer Therapeutics, Global, Treatment Use Patterns and Market Size, 2013-2020
  • Figure 22: Ovarian Cancer Therapeutics, India, Treatment Use Patterns ('000), 2013-2020
  • Figure 23: Ovarian Cancer Therapeutics, India, Annual Cost of Therapy ($), 2013-2020
  • Figure 24: Ovarian Cancer Therapeutics: India, Market Size ($m), 2013-2020
  • Figure 25: Ovarian Cancer Therapeutics, China, Treatment Use Patterns ('000), 2013-2020
  • Figure 26: Ovarian Cancer Therapeutics, China, Annual Cost of Therapy ($), 2013-2020
  • Figure 27: Ovarian Cancer Therapeutics: China, Market Size ($m), 2013-2020
  • Figure 28: Ovarian Cancer Therapeutics, Japan, Treatment Use Patterns ('000), 2013-2020
  • Figure 29: Ovarian Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 2013-2020
  • Figure 30: Ovarian Cancer Therapeutics: Japan, Market Size ($m), 2013-2020
  • Figure 31: Ovarian Cancer Therapeutics, Australia, Treatment Use Patterns ('000), 2013-2020
  • Figure 32: Ovarian Cancer Therapeutics, Australia, Annual Cost of Therapy ($), 2013-2020
  • Figure 33: Ovarian Cancer Therapeutics: Australia, Market Size ($m), 2013-2020
  • Figure 34: Ovarian Cancer Therapeutics, Global, Licensing Deals by Location, Year and Value, 2006-2014
  • Figure 35: Ovarian Cancer Therapeutics, Global, Licensing Deals by Phase, Molecule Type and Mechanism of Action, 2006-2014
  • Figure 36: Ovarian Cancer Therapeutics, Global, Co-development Deals by Location, Year and Value, 2006-2014
  • Figure 37: GBI Research Market Forecasting Model
Back to Top